Tonsillectomy and Primitive IgA Nephropathy in Children: Strasbourg Cohort and Assessment Practices in Inter North East Region

NCT02829164 | Unknown

• 1 other identifier: 6402
• Study Type: observational
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

Primitive kidney disease IgA, represented by Berger's disease and rheumatoid purpura nephropathy, are the first cause of kidney failure from chronic glomerulonephritis: changes in 20 years to end-stage renal failure is described in 10 to 30 % of cases in Berger's disease and in 15 to 20% of cases in nephropathy HSP. These two pathological entities share biological and histological characteristics, as well as common pathophysiological mechanisms, particularly the production of abnormally glycosylated IgA1 promoting their proliferation in the mesangium. Tonsils part of Iga abnormal production sites that would be associated with an infectious stimulus, tonsillectomy has been studied as a possible treatment in primitive IgA nephropathy. The benefit of tonsillectomy is controversial: many Japanese studies demonstrate its effectiveness in terms of reduction of proteinuria, improved renal function in the long term regression of histological lesions and reduced risk of relapse following clinical remission whereas European studies do not suggest its effectiveness in treating IgA nephropathy. In this context, the aim of our study is to describe the scope of practice of tonsillectomy in the treatment of primary renal disease in IgA child in the inter East region and describe the short renal become Strasbourg end of the cohort that received this treatment.

Conditions

Tonsillectomy

Keywords

Tonsillectomy; primary IgA nephropathy; primary nephropathy; IgA; Berger's disease; Purpura rheumatoid; kidney failure

Outcome Measures

Primary Outcomes (1)

• Evaluation of the management of the tonsillectomy at the CHU of Strasbourg by a standardized questionnaire

  since January 2009

Eligibility Criteria

• Age: Up to 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Children with a clinical diagnosis and / or histological evidence of primary IgA nephropathy

You may qualify if:

• Children with a clinical diagnosis and / or histological evidence of primary IgA nephropathy
• Follow the University Hospital of Strasbourg since 2009
• Having received a tonsillectomy in their care
• Children whose holders of parental authority does not oppose the use of clinical data from their child for research purposes

You may not qualify if:

• Children whose holders of parental authority are opposed to the use of clinical data from their child for research purposes

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service de Pédiatrie 1 Hôpital de Hautepierre

Strasbourg, 67098, France

RECRUITING

MeSH Terms

Conditions

Glomerulonephritis, IGA; IgA Vasculitis; Renal Insufficiency

Condition Hierarchy (Ancestors)

Glomerulonephritis; Nephritis; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Autoimmune Diseases; Immune System Diseases; Vasculitis; Vascular Diseases; Cardiovascular Diseases; Purpura; Blood Coagulation Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemostatic Disorders; Hemorrhagic Disorders; Skin Diseases, Vascular; Skin Diseases; Skin and Connective Tissue Diseases; Immune Complex Diseases; Hypersensitivity; Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Skin Manifestations; Signs and Symptoms

Study Officials

• Laetitia HIGEL, MD

  University Hospital, Strasbourg, France

  STUDY DIRECTOR

Central Study Contacts

Laetitia HIGEL, MD

CONTACT

33 (0)3.88.12.77.40; laetitia.higel@chru-strasbourg.fr

Eléonore FEUGEAS, MD

CONTACT

33 (0)3.88.12.77.40; Eleonore.feugeas@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 16, 2016
• First Posted: July 12, 2016
• Study Start: April 1, 2016
• Primary Completion: September 1, 2017
• Study Completion: September 1, 2017
• Last Updated: May 23, 2017

Record last verified: 2017-05

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)